Pfizer, BioNTech Halt US COVID Vaccine Study After Recruitment Struggles

What's Going On With Pfizer Stock Wednesday? - BioNTech (NASDAQ:BNTX), Pfizer (NYSE:PFE)

Pfizer & BioNTech halt recruitment for a major U.S. COVID vaccine trial for adults 50–64 due to low enrollment. Read the latest updates.

Pfizer and BioNTech Pause COVID-19 Vaccine Trial Due to Low Enrollment

Pfizer and BioNTech have stopped their large U.S. COVID-19 vaccine trial in adults aged 50 to 64, citing insufficient enrollment to generate necessary data. The trial faced recruitment challenges, with over 80% of interested participants failing pre-screening due to health criteria. Moderna continues its similar study.

Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too low to generate the needed data.

Pfizer, BioNTech halt US trial of COVID-19 vaccine over low enrollment

Pfizer and BioNTech have halted a major U.S. clinical trial of their updated COVID-19 vaccine in adults aged 50 to 64, citing insufficient participant...

Pfizer, BioNTech halt U.S. COVID vaccine trial (PFE:NYSE)

Pfizer (PFE) stock and BioNTech (BNTX) stock are in focus as a large U.S. trial for the companies' updated COVID-19 vaccine ends due to low enrollments. Read more here.